Trials / Withdrawn
WithdrawnNCT02410239
MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)
MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD)
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).
Detailed description
This is a single-institution dose escalation study to determine the maximum tolerated dose (MTD) of intrathecally administered allogeneic, 3rd party mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mesenchymal Stem Cells |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-07-01
- Completion
- 2022-07-01
- First posted
- 2015-04-07
- Last updated
- 2017-12-02
Source: ClinicalTrials.gov record NCT02410239. Inclusion in this directory is not an endorsement.